US 12,227,581 B2
Anti-BCMA single domain antibodies and application thereof
Jishuai Zhang, Shenzhen (CN); Hongjian Li, Shenzhen (CN); Chaolemeng Bao, Shenzhen (CN); Qinghua Cai, Shenzhen (CN); Yingying Li, Shenzhen (CN); Zongpei Song, Shenzhen (CN); Yijin Ding, Shenzhen (CN); and Zhibo Cai, Shenzhen (CN)
Assigned to SHENZHEN PREGENE BIOPHARMA CO., LTD., Shenzhen (CN)
Appl. No. 17/270,788
Filed by SHENZHEN PREGENE BIOPHARMA CO. LTD., Shenzhen (CN)
PCT Filed Jul. 10, 2019, PCT No. PCT/CN2019/095507
§ 371(c)(1), (2) Date Feb. 23, 2021,
PCT Pub. No. WO2020/038147, PCT Pub. Date Feb. 27, 2020.
Claims priority of application No. 201810972054.2 (CN), filed on Aug. 24, 2018.
Prior Publication US 2022/0251226 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 16/2878 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464417 (2023.05); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2319/33 (2013.01)] 11 Claims
 
1. An anti-BCMA (B cell maturation antigen) single domain antibody, comprising framework regions and complementarity determining regions, wherein the complementarity determining regions comprise the amino acid sequences of CDR1, CDR2, and CDR3 in SEQ ID NO: 67.